

**DERMATOLOGIC AND OPHTHALMIC DRUGS ADVISORY COMMITTEE
MEETING ROSTER**

*Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Advisory Committee Conference Room, Rm. 1066,
5630 Fishers Lane, Rockville, MD
May 29, 2008*

**DERMATOLOGIC AND OPHTHALMIC DRUGS ADVISORY COMMITTEE
MEMBERS (VOTING)**

Marijean M. Miller, M.D. (*Acting Chair*)
Attending Physician
Department of Ophthalmology
Children's National Medical Center
Washington, District of Columbia

**DERMATOLOGIC AND OPHTHALMIC DRUGS ADVISORY COMMITTEE
MEMBERS (NON-VOTING)**

Ellen Strahlman, M.D., M.H.Sc. (*Non-Voting
Industry Representative*)
Vice President, Worldwide Business Development
Pfizer, Incorporated
New York, New York

TEMPORARY VOTING MEMBERS

Joel Mindel, M.D., Ph.D.
Director of Neuro-ophthalmology
Mount Sinai Medical Center
New York, New York

Scott M. Steidl, M.D.
Eyecare Medical Group
Portland Maine

Paula Cofer (*Patient Representative*)
Brandon, Florida

**FDA CENTER FOR DRUG EVALUATION AND RESEARCH PARTICIPANTS (NON-
VOTING)**

Edward M. Cox, M.D., M.P.H.
Acting Director, Office of Antimicrobial
Products (OAP)
FDA, CDER
Sonal Wadhwa, M.D.
Clinical Reviewer
DAIOP, CDER, FDA

Wiley Chambers, M.D.
Acting Director, Division of Division of Anti-
Infective and Ophthalmic Products (DAIOP)
FDA, CDER